Existing user? Login

Cardiovascular disease

High-risk HPV infection linked to increased risk of cardiovascular disease

Looking at data from more than 60,000 Korean women, researchers found the risk of cardiovascular disease was 25% higher in those with high-risk human papillomavirus (HPV) infection, and 73% higher in obese women with high-risk HPV.

Coloured transmission electron micrograph (TEM) of human papillomavirus

Source: Phanie / Alamy Stock Photo

Overall, the analysis revealed that the risk of cardiovascular disease was 25% higher in those with high-risk human papillomavirus (HPV) infection (micrograph pictured) compared with those without HPV

Women with high-risk human papillomavirus (HPV) infection are more likely to develop cardiovascular disease (CVD) than those without, the results of a study published in Circulation Research suggest (7 February 2019)[1]. 

Researchers looked at data from 63,411 healthy Korean women aged 30 years and over who were tested for HPV and followed-up every one or two years between 2011 and 2016. In total, 7.6% had high-risk HPV infection when first tested, with 1,122 new cases of CVD detected during follow-up.

Overall, after adjustment for confounding factors, the analysis revealed that the risk of CVD was 25% higher in those with high-risk HPV infection compared with those without HPV.

The authors found that the association between high-risk HPV and CVD was stronger in obese individuals than non-obese; the adjusted risk of CVD was 73% in obese participants with HPV compared with 10% in non-obese participants with HPV. A similar pattern was found in those with metabolic syndrome compared with those without.

The researchers said the findings suggested that high-risk HPV infection may act additively or synergistically with obesity and metabolic syndrome to increase cardiovascular disease risk, potentially related to effects on inflammation.

The authors concluded: “Further studies are required to identify the specific high-risk HPV genotypes that may contribute to CVD and implement vaccine strategies as a modifiable risk factor for the reduction of CVD, in addition to prevention of anogenital cancers.”

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206265

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

  • Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

  • Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

  • International Research in Healthcare

    Guidance for students or researchers undertaking a multi-centre research project in health services, medicines use and professional practice.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.


химчистка ковра

surrogacy baby